

HELSINN: MARY LYNNE HEDLEY APPOINTED TO BOARD OF DIRECTORS

Posted on 29 April 2021



Category: [News](#)

Tags: [Mary Lynne Hedley](#), [News](#)



Helsinn – the Swiss pharmaceutical group focused on building quality cancer care and rare disease products – is pleased to announce the appointment of **Mary Lynne Hedley** as a new member of its board of directors, effective April 28, 2021.

Hedley was director, president and chief operating officer at Tesaro, a biotechnology company she co- founded in 2010, focused on the development and global commercialization of oncology therapeutics.

She was executive vice president and cso of the biotechnology company, Abraxis Bioscience, responsible for R&D, Operations, Medical Affairs and Business Development. Elsewhere she was executive vice president of Eisai, with a focus on the global reorganization of its R&D program and building a global oncology strategy. She was also Executive Vice President, as well as cso, responsible for R&D, at MGI PHARMA (MGI) until its acquisition by Eisai in 2008. In addition, she was co-founder, director, president and ceo of ZYCOS prior to its acquisition by MGI in 2004.